Last reviewed · How we verify
Non-small cell lung cancer with mutation in epidermal growth factor receptor
Approved treatments
- Avastin · Washington University School of Medicine
- Bevacizumab · Roche
Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR. - Avastin · Roche
Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Non-small cell lung cancer with mutation in epidermal growth factor receptor patent landscape — cliff calendar, originator estates, attackable patents
- Non-small cell lung cancer with mutation in epidermal growth factor receptor treatment landscape brief
- Non-small cell lung cancer with mutation in epidermal growth factor receptor treatment updates RSS
Frequently asked questions about Non-small cell lung cancer with mutation in epidermal growth factor receptor
What drugs treat Non-small cell lung cancer with mutation in epidermal growth factor receptor?
Tracked treatments include Avastin, Bevacizumab.
What is the treatment for Non-small cell lung cancer with mutation in epidermal growth factor receptor?
Standard treatment for Non-small cell lung cancer with mutation in epidermal growth factor receptor includes Avastin, Bevacizumab. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Non-small cell lung cancer with mutation in epidermal growth factor receptor patent cliff · Non-small cell lung cancer with mutation in epidermal growth factor receptor CI report
- Treatment: Avastin · Washington University School of Medicine
- Treatment: Bevacizumab · Roche
- Treatment: Avastin · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing